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1 Introduction
For many years, the National Institute for Health and Care
Excellence (NICE) has recommended use of the EQ-5D-3L
(3L) [1] and its value set for the UK [2]. Since 2011, an
expanded-level instrument, the EQ-5D-5L (5L), has been
available [3] and value sets now exist to support its use,
including a value set for England [4, 5]. This poses a challenge
for NICE. Should it recommend the 5L rather than the 3L?
This is neither a trivial nor merely academic matter: the
choice of whether to use the 5L (and English value set) or
the 3L (and UK value set) is likely to impact estimates of
quality-adjusted life-years (QALYs) and incremental cost-
effectiveness ratios (ICERs). The size and direction of that
impact will depend on the disease and the nature of the
health problems. In general, where technologies improve
self-reported health, estimates of QALY gains will often be
smaller with the 5L [6]. In contrast, where technologies
extend the length of life, estimates of QALY gains will be
higher (to varying degrees): each year of additional life is
assigned a higher utility. The ultimate impact on health
technology assessment (HTA) will depend on whether the
differences between the 3L and 5L push ICERs from one
side of the cost-effectiveness threshold to the other.
Given the implications for NICE’s technology appraisal
process, and other decisions informed by EQ-5D data, the
Department of Health for England has called for an inde-
pendent validation of the 5L value set, given its relevance
to policy [7].
In 2017, NICE released a ‘position statement’ [8] stating
that:
1. The 3L value set continues to be used for reference-
case analyses.
2. Where 5L data have been collected, reference-case
analyses should calculate utilities by mapping the 5L
descriptive system data onto the 3L value set, using the
van Hout et al. [9] mapping function.
3. NICE supports sponsors of prospective clinical studies
continuing to use the 5L to collect data on quality of life.
A further position statement is planned for August 2018,
to be informed by evidence from various studies underway.
These include studies commissioned by the English
Department of Health to investigate the implications for
past NICE technology appraisals had the 5L been used, and
to collect 3L and 5L data in parallel to further improve
functions for mapping from one to the other. Other studies,
funded by the EuroQol Group, are also underway, inves-
tigating various aspects of the relationship between the 3L
and 5L across disease areas.
The 3L and its UK value set has occupied a special place
in NICE’s technology appraisal process since its inception,
therefore any transition will inevitably pose challenges; for
example, reconciling potential inconsistencies between
past and future decisions. Given that evidence will continue
to be submitted using both the 3L and 5L for years to come,
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if both value sets are able to be used, there is a risk of
inconsistency between decisions being made in the future.
HTA in other countries may also face similar issues.
Given the difficulties with any transition away from the
3L, is there a case for NICE to adopt the 5L as its preferred
instrument? Papers in this issue of Pharmacoeconomics,
which are cited in this commentary, address that question
by investigating comparative performance of the 3L and
5L.
2 3L vs. 5L Descriptive Systems
There are two sources of differences between the 3L and
the 5L: [1] the way they describe patient health via the
health state classifier; and [2] the way they value health
using preferences obtained from the general public. It is the
combination of these two key elements that determines
estimates of QALYS. Therefore, an assessment of the
merits of the two instruments needs to consider both.
While the 3L and 5L contain the same five dimensions,
there are other, important differences between them. Most
obviously, the 5L has increased the number of levels from
3 to 5 and the total number of health states described from
243 to 3125. There are also differences in the descriptors,
most notably for the worst level of mobility: ‘confined to
bed’ in the 3L has been replaced with ‘unable to walk
about’ in the 5L.
Because of its expanded-level structure, the 5L has the
potential to capture the health of subjects more accurately
than the 3L, but there is an increase in cognitive burden
from offering more choice that may result in lower
response rates and perhaps greater measurement error from
not knowing which level to choose. Ultimately any mea-
surement benefits from the increased descriptive system
must be empirically demonstrated. Papers in this issue, as
well as others recently published, suggest these advantages
are being realised. Advantages of the 5L over the 3L
include:
(a) A reduction in the ceiling effect: The 3L suffers from
a ceiling effect, i.e. respondents reporting no problems on
any dimension despite (e.g. slight) problems being present.
The effect is reinforced by the large gap, in most 3L value
sets, between full health and the next best state (in the 3L
UK value set, valued at 0.88). In many 3L studies, more
than 40% of subjects self-report full health, which dropped
by 10% using the 5L [10–12]. Larger and smaller reduc-
tions in ceiling effects have been reported elsewhere,
reflecting differences in the study samples, e.g. [13–15].
(b) Reduced clustering on just a few states: The lack of
granularity in the 3L descriptive system imposes con-
straints on the self-report of health. Observations tend to
cluster on a few health states [15, 16]. The 5L consistently
produces considerably more unique health states than the
3L, as shown by Buchholz et al. [17]. For example, Feng
et al. [18] reported that just three health states accounted
for almost 75% of respondents on the 3L, while a similar
proportion of respondents on the 5L were accounted for by
12 health states.
The clustering of descriptive data on the 3L is also
reflected in the characteristics of utility-weighted 3L data.
3L health states are relatively far apart on the value scale;
for example, the presence or absence of extreme problems
in practice predicts almost perfectly whether utility is
above or below 0.5. The distribution of utility-weighted 5L
data is less prone to this sort of artefactual clustering [16].
(c) Improved ability to discriminate between patient
groups/subgroups: The 5L has better discriminative ability,
as demonstrated by improved ability to detect differences
between subgroups defined by severity at a given sample
size [13, 19, 20]. 5L users thus benefit from lower sample
size requirements within samples of patients [21].
Although the 3L seemingly has better ability to detect
differences between patients and a general population
group, this is an artefact [13, 17]. The 5L has improved
ability to measure health accurately at the top of the scale
and therefore provides finer differences between mild ill-
health states and full health at the top of the scale, whereas
the 3L has much larger steps between levels 2 and 1. As a
result, the 3L can overestimate health gains and produce
biased ICERs.
(d) Improvements in the 5L with respect to problems
with mobility: Abandoning the 3L level 3 descriptor
‘confined to bed’ constitutes an important improvement in
the 5L. Level 3 problems on mobility are rarely observed in
3L data. For example, among patients about to receive hip
replacement surgery in the National Health Service, none
reported a level 3 problem [22]. In effect, in most settings,
the 3L only has two dimensions on mobility: no and some
problems. Consequently, the 3L will underestimate benefits
of treatments that improve severe problems with mobility
[13].
Overall, this evidence suggests that the 5L retains the
benefits of 3L—its brevity and validity in a wide range of
conditions—and produces a more accurate measurement of
patient health than the 3L. At the same time, there is no
evidence for lower completion rates, and the increase in the
number of levels has reduced the amount of variability.
3 5L Versus 3L Utilities
The impact on HTA of the differences between the 3L and
5L descriptive systems becomes apparent only after
attaching health state values, the properties of which vary
between value sets.
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Mulhern et al. [23] point to important differences
between the UK 3L and England 5L value sets. Compared
with the 3L value set, the entire distribution of the 5L
values has shifted to the right and has a shorter tail. The
minimum value is higher and there are substantially fewer
values\0. While the distribution of 3L values has larger
gaps, 5L values show a more even distribution.
Are these differences improvements? Until the external
validation of the England 5L value set concludes, the jury
is still out. But it is instructive to reflect on the causes of
these differences.
First, there are differences in the preferences data they
are based on. Both used time trade-off (TTO), but val-
ues\0 were elicited very differently. Furthermore, the 5L
value set uses both TTO and discrete choice experiment
(DCE) data. The value sets were generated at different
points in time (1997 vs. 2017) and preferences for health
may have changed in the interval—a potential reason to
revisit value sets for all preference-based measures [24].
Furthermore, the 5L valuation protocol [25] benefited from
two decades of methodological advances. Paired with the
additional change in descriptors in the mobility dimension,
there is no reason to expect that 3L and 5L would produce
the same values.
Second, there are differences in the way the value sets
are modelled. While the 3L value set model has the merit
of simplicity, the 5L value set uses innovative modelling
approaches, e.g. addressing preference heterogeneity and
combining TTO and DCE data via ‘hybrid’ models [5]. The
realization that simple models can produce biased values
has led to advances in modelling TTO data [26, 27]. With
5L valuation studies being conducted in the digital era,
researchers have access to metadata (e.g. respondents’
patterns of trading), which reveal the influence of the TTO
design task on values. New methods can control for this.
In comparing the UK 3L and England 5L value sets, it
should be noted that some of these differences arise
because the former is somewhat unusual (e.g. compared
with most other countries’ 3L value sets). It has a high
percentage of health states with negative values (over one-
third of the 243 states have values\0, indicating that, on
average, the general public considered them ‘worse than
being dead’). A 1996 UK replication study by Kind and
Macran [28], using the same protocol, found just 12% of
states were\0. In comparison, 5% of the values in the
England 5L value set are\0. Similarly, the minimum
value in the UK 3L value set (- 0.594) is much lower than
that in the replication study (- 0.126). In comparison, the
minimum value in the England 5L value set study is -
0.285. Similar conclusions with respect to the UK 3L value
set were also reported by Tsuchiya et al. [29].
In summary, there are many reasons why the UK 3L and
England 5L value sets are different. Some of these reasons
apply to all countries with 3L and 5L value sets, while
others are specific to the UK/England case. The England
5L value set was one of the first 5L value set studies
undertaken internationally, and learning from it benefitted
subsequent studies. For example, detailed reporting of
issues observed in the English data led to improvements in
the protocol and data quality monitoring in subsequent
studies. Nevertheless, comparison of the England 5L value
set with other 5L value sets shows a broad level of
agreement between them [30].
4 Concluding Remarks
The 5L was developed to improve on an instrument (the
3L), which has been widely used and has validity in a wide
range of conditions. As summarised in this commentary,
the 5L has a number of advantages over the 3L as a
measure of self-reported health.
NICE’s position statement does not signal a concern
about the 5L descriptive system. Rather, it is a reaction to a
governmental requirement to validate the England 5L value
set that accompanies it.
As a decision-making entity that bears responsibility to a
range of stakeholders, NICE is responding to the avail-
ability of a 5L value set with understandable care. QALY
gains are often very small, therefore ICERs can be highly
sensitive to the choice of value set. This underlines the
importance of ensuring that any new value set is valid for
use in decisions about cost effectiveness. Until that work
concludes, the status of the England 5L value set is (to coin
a NICE phrase) ‘in research only’ rather than
‘recommended’.
However, what is increasingly clear is that much of
the difference noted between the UK 3L and England 5L
value sets is attributable to characteristics of the former.
It is fairly unlikely that any new value set, whether that
be for the 3L or the 5L, will have the same properties as
the existing UK 3L value set, suggesting that the tran-
sitional challenge facing NICE is unavoidable. The
papers in this issue help to shed light on the compara-
bility of the 3L and 5L, and provide evidence to help
inform that transition.
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